Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
187 hedge funds and large institutions have $1.92B invested in Esperion Therapeutics in 2018 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 69 increasing their positions, 54 reducing their positions, and 17 closing their positions.
135% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 17
28% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 54
20% more capital invested
Capital invested by funds: $1.6B → $1.92B (+$321M)
13% more funds holding
Funds holding: 165 → 187 (+22)
7.25% more ownership
Funds ownership: 92.75% → 100% (+7.2%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
36% less call options, than puts
Call options by funds: $84.4M | Put options by funds: $131M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.5M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$28M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$22.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$20.3M |
| 2 |
Millennium Management
New York
|
-$18.6M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.6M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$15.1M |
| 5 |
Goldman Sachs
New York
|
-$10.5M |
ESPR Hedge Fund Activity: Q1 2018 in Review
187 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2018, worth a combined $1.92B — up 20% from $1.6B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ESPR positions and 17 closed out — a net gain of 23 holders — while 69 added to existing stakes and 54 trimmed.
The largest buyer was Vanguard Group, adding an estimated $40.7M. The largest seller was Discovery Capital Management, cutting an estimated $20.3M.
- 187 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2018, up from 165 in Q4 2017.
- Funds reported $1.92B of Esperion Therapeutics stock for Q1 2018, up 20% quarter-over-quarter.
- 40 funds opened new Esperion Therapeutics positions in Q1 2018 and 17 closed out, a net change of +23 holders.
- The largest Esperion Therapeutics buyer in Q1 2018 was Vanguard Group, an estimated $40.7M added.
- The largest Esperion Therapeutics seller in Q1 2018 was Discovery Capital Management, an estimated $20.3M sold.
Based on aggregated 13F filings for Q1 2018.